|
1
|
Nakamura T, Nishizawa T, Hagiya M, Seki T,
Shimonishi M, Sugimura A, Tashiro K and Shimizu S: Molecular
cloning and expression of human hepatocyte growth factor. Nature.
342:440–443. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matsumoto K, Okazaki H and Nakamura T:
Up-regulation of hepatocyte growth factor gene expression by
interleukin-1 in human skin fibroblasts. Biochem Biophys Res
Commun. 188:235–243. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brinkmann V, Foroutan H, Sachs M, Weidner
KM and Birchmeier W: Hepatocyte growth factor/scatter factor
induces a variety of tissue-specific morphogenic programs in
epithelial cells. J Cell Biol. 131:1573–1586. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schmidt C, Bladt F, Goedecke S, Brinkmann
V, Zschiesche W, Sharpe M, Gherardi E and Birchmeier C: Scatter
factor/hepatocyte growth factor is essential for liver development.
Nature. 373:699–702. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bussolino F, Di Renzo MF, Ziche M,
Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer
A and Comoglio PM: Hepatocyte growth factor is a potent angiogenic
factor which stimulates endothelial cell motility and growth. J
Cell Biol. 119:629–641. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Renzo MF, Olivero M, Giacomini A, Porte
H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S,
Giordano S, Plebani M, Gespach C and Comoglio PM: Overexpression
and amplification of the met/HGF receptor gene during the
progression of colorectal cancer. Clin Cancer Res. 1:147–154.
1995.PubMed/NCBI
|
|
7
|
Matsumoto K and Nakamura T: Emerging
multipotent aspects of hepatocyte growth factor. J Biochem.
119:591–600. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miller CT, Lin L, Casper AM, Lim J, Thomas
DG, Orringer MB, Chang AC, Chambers AF, Giordano TJ, Glover TW and
Beer DG: Genomic amplification of MET with boundaries within
fragile site FRA7G and upregulation of MET pathways in esophageal
adenocarcinoma. Oncogene. 25:409–418. 2006.PubMed/NCBI
|
|
10
|
Grant DS, Kleinman HK, Goldberg ID,
Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P and Rosen EM:
Scatter factor induces blood vessel formation in vivo. Proc Natl
Acad Sci USA. 90:1937–1941. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Di Renzo MF, Poulsom R, Olivero M,
Comoglio PM and Lemoine NR: Expression of the Met/hepatocyte growth
factor receptor in human pancreatic cancer. Cancer Res.
55:1129–1138. 1995.PubMed/NCBI
|
|
12
|
Nakamura T, Matsumoto K, Kiritoshi A, Tano
Y and Nakamura T: Induction of hepatocyte growth factor in
fibroblasts by tumor-derived factors affects invasive growth of
tumor cells: in vitro analysis of tumor-stromal interactions.
Cancer Res. 57:3305–3313. 1997.
|
|
13
|
Date K, Matsumoto K, Shimura H, Tanaka M
and Nakamura T: HGF/NK4 is a specific antagonist for pleiotrophic
actions of hepatocyte growth factor. FEBS Lett. 420:1–6. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuba K, Matsumoto K, Date K, Shimura H,
Tanaka M and Nakamura T: HGF/NK4, a four-kringle antagonist of
hepatocyte growth factor, is an angiogenesis inhibitor that
suppresses tumor growth and metastasis in mice. Cancer Res.
60:6737–6743. 2000.PubMed/NCBI
|
|
15
|
Matsumoto K and Nakamura T: Mechanisms and
significance of bifunctional NK4 in cancer treatment. Biochem
Biophys Res Commun. 333:316–327. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saimura M, Nagai E, Mizumoto K, Maehara N,
Minamishima YA, Katano M, Matsumoto K, Nakamura T and Tanaka M:
Tumor suppression through angiogenesis inhibition by SUIT-2
pancreatic cancer cells genetically engineered to secrete NK4. Clin
Cancer Res. 8:3243–3249. 2002.
|
|
17
|
Tomioka D, Maehara N, Kuba K, Mizumoto K,
Tanaka M, Matsumoto K and Nakamura T: Inhibition of growth,
invasion, and metastasis of human pancreatic carcinoma cells by NK4
in an orthotopic mouse model. Cancer Res. 61:7518–7524.
2001.PubMed/NCBI
|
|
18
|
Kubota T, Fujiwara H, Amaike H, Takashima
K, Inada S, Atsuji K, Yoshimura M, Matsumoto K, Nakamura T and
Yamagishi H: Reduced HGF expression in subcutaneous CT26 tumor
genetically modified to secrete NK4 and its possible relation with
antitumor effects. Cancer Sci. 95:321–327. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gerritsen ME, Tomlinson JE, Zlot C, Ziman
M and Hwang S: Using gene expression profiling to identify the
molecular basis of the synergistic actions of hepatocyte growth
factor and vascular endothelial growth factor in human endothelial
cells. Br J Pharmacol. 140:595–610. 2003. View Article : Google Scholar
|
|
20
|
Wojta J, Kaun C, Breuss JM, Koshelnick Y,
Beckmann R, Hattey E, Mildner M, Weninger W, Nakamura T, Tschachler
E and Binder BR: Hepatocyte growth factor increases expression of
vascular endothelial growth factor and plasminogen activator
inhibitor-1 in human keratinocytes and the vascular endothelial
growth factor receptor flk-1 in human endothelial cells. Lab
Invest. 79:427–438. 1999.
|
|
21
|
Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC
and Van Waes C: Hepatocyte growth factor/scatter factor-induced
activation of MEK and PI3K signal pathways contributes to
expression of proangiogenic cytokines interleukin-8 and vascular
endothelial growth factor in head and neck squamous cell carcinoma.
Cancer Res. 61:5911–5918. 2001.
|
|
22
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar
|
|
23
|
Whiteside TL: The tumor microenvironment
and its role in promoting tumor growth. Oncogene. 27:5904–5912.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kuperwasser C, Chavarria T, Wu M, Magrane
G, Gray JW, Carey L, Richardson A and Weinberg RA: Reconstruction
of functionally normal and malignant human breast tissues in mice.
Proc Natl Acad Sci USA. 101:4966–4971. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Wever O and Mareel M: Role of tissue
stroma in cancer cell invasion. J Pathol. 200:429–447.
2003.PubMed/NCBI
|
|
26
|
Pietras K, Sjöblom T, Rubin K, Heldin CH
and Ostman A: PDGF receptors as cancer drug targets. Cancer Cell.
3:439–443. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kitadai Y: Cancer-stromal cell interaction
and tumor angiogenesis in gastric cancer. Cancer Microenviron.
3:109–116. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matsumoto K, Date K, Shimura H and
Nakamura T: Acquisition of invasive phenotype in gallbladder cancer
cells via mutual interaction of stromal fibroblasts and cancer
cells as mediated by hepatocyte growth factor. Jpn J Cancer Res.
87:702–710. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung
L, Chen Y, Huang X, Chan HM, Zhao P, Luk J, Vande Woude G and Wong
J: Hepatocyte growth factor promotes cancer cell migration and
angiogenic factors expression: a prognostic marker of human
esophageal squamous cell carcinomas. Clin Cancer Res. 11:6190–6197.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kaposi-Novak P, Lee JS, Gòmez-Quiroz L,
Coulouarn C, Factor VM and Thorgeirsson SS: Met-regulated
expression signature defines a subset of human hepatocellular
carcinomas with poor prognosis and aggressive phenotype. J Clin
Invest. 116:1582–1595. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moriyama T, Kataoka H, Hamasuna R,
Yokogami K, Uehara H, Kawano H, Goya T, Tsubouchi H, Koono M and
Wakisaka S: Up-regulation of vascular endothelial growth factor
induced by hepatocyte growth factor/scatter factor stimulation in
human glioma cells. Biochem Biophys Res Commun. 249:73–77. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Matsumura A, Kubota T, Taiyoh H, Fujiwara
H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S, Nakanishi M, Kuriu
Y, Murayama Y, Ikoma H, Ochiai T, Kokuba Y, Nakamura T, Matsumoto K
and Otsuji E: HGF regulates VEGF expression via the c-Met receptor
downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine
cells. Int J Oncol. 42:535–542. 2013.PubMed/NCBI
|
|
33
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
